245 related articles for article (PubMed ID: 15162895)
1. Sulfonylurea treatment of type 2 diabetes mellitus: focus on glimepiride.
Korytkowski MT
Pharmacotherapy; 2004 May; 24(5):606-20. PubMed ID: 15162895
[TBL] [Abstract][Full Text] [Related]
2. Glimepiride. A review of its use in the management of type 2 diabetes mellitus.
Langtry HD; Balfour JA
Drugs; 1998 Apr; 55(4):563-84. PubMed ID: 9561345
[TBL] [Abstract][Full Text] [Related]
3. The effect of glimepiride on pancreatic beta-cell function under hyperglycaemic clamp and hyperinsulinaemic, euglycaemic clamp conditions in non-insulin-dependent diabetes mellitus.
Clark HE; Matthews DR
Horm Metab Res; 1996 Sep; 28(9):445-50. PubMed ID: 8911981
[TBL] [Abstract][Full Text] [Related]
4. [Glimepiride (Amaryl): a review of its pharmacological and clinical profile].
Bando K; Yamada Y
Nihon Yakurigaku Zasshi; 2001 Jul; 118(1):59-67. PubMed ID: 11496829
[TBL] [Abstract][Full Text] [Related]
5. [Glimepiride--an oral antidiabetic agent].
Becić F; Kapić E; Becić E
Med Arh; 2003; 57(2):125-7. PubMed ID: 12822388
[TBL] [Abstract][Full Text] [Related]
6. Beta cell response to oral glimepiride administration during and following a hyperglycaemic clamp in NIDDM patients.
van der Wal PS; Draeger KE; van Iperen AM; Martini C; Aarsen M; Heine RJ
Diabet Med; 1997 Jul; 14(7):556-63. PubMed ID: 9223393
[TBL] [Abstract][Full Text] [Related]
7. Effect of linagliptin compared with glimepiride on postprandial glucose metabolism, islet cell function and vascular function parameters in patients with type 2 diabetes mellitus receiving ongoing metformin treatment.
Forst T; Anastassiadis E; Diessel S; Löffler A; Pfützner A
Diabetes Metab Res Rev; 2014 Oct; 30(7):582-9. PubMed ID: 24459063
[TBL] [Abstract][Full Text] [Related]
8. [Glimepiride in daily practice].
Jasik M
Przegl Lek; 2003; 60(6):409-12. PubMed ID: 14974179
[TBL] [Abstract][Full Text] [Related]
9. Insulin secretagogues: who, what, when, and how?
Dailey G
Curr Diab Rep; 2005 Oct; 5(5):329-32. PubMed ID: 16188166
[TBL] [Abstract][Full Text] [Related]
10. Kinetics-effect relations of insulin-releasing drugs in patients with type 2 diabetes: brief overview.
Melander A
Diabetes; 2004 Dec; 53 Suppl 3():S151-5. PubMed ID: 15561903
[TBL] [Abstract][Full Text] [Related]
11. A prospective trial of risk factors for sulfonylurea-induced hypoglycemia in type 2 diabetes mellitus.
Burge MR; Schmitz-Fiorentino K; Fischette C; Qualls CR; Schade DS
JAMA; 1998 Jan; 279(2):137-43. PubMed ID: 9440664
[TBL] [Abstract][Full Text] [Related]
12. Comparison of mortality and cardiovascular event risk associated with various insulin secretagogues: A nationwide real-world analysis.
Huang HK; Yeh JI
Diabetes Res Clin Pract; 2019 Jun; 152():103-110. PubMed ID: 31108137
[TBL] [Abstract][Full Text] [Related]
13. Clinical evaluation of glimepiride versus glyburide in NIDDM in a double-blind comparative study. Glimepiride/Glyburide Research Group.
Dills DG; Schneider J
Horm Metab Res; 1996 Sep; 28(9):426-9. PubMed ID: 8911977
[TBL] [Abstract][Full Text] [Related]
14. Short-term comparison of once- versus twice-daily administration of glimepiride in patients with non-insulin-dependent diabetes mellitus.
Sonnenberg GE; Garg DC; Weidler DJ; Dixon RM; Jaber LA; Bowen AJ; DeChemey GS; Mullican WS; Stonesifer LD
Ann Pharmacother; 1997 Jun; 31(6):671-6. PubMed ID: 9184703
[TBL] [Abstract][Full Text] [Related]
15. The role of glimepiride in the effective management of Type 2 diabetes.
Davis SN
J Diabetes Complications; 2004; 18(6):367-76. PubMed ID: 15531188
[TBL] [Abstract][Full Text] [Related]
16. Repaglinide is more efficient than glimepiride on insulin secretion and post-prandial glucose excursions in patients with type 2 diabetes. A short term study.
Rizzo MR; Barbieri M; Grella R; Passariello N; Barone M; Paolisso G
Diabetes Metab; 2004 Feb; 30(1):81-9. PubMed ID: 15029102
[TBL] [Abstract][Full Text] [Related]
17. Efficacy of sulfonylureas with insulin in type 2 diabetes mellitus.
Kabadi MU; Kabadi UM
Ann Pharmacother; 2003 Nov; 37(11):1572-6. PubMed ID: 14565810
[TBL] [Abstract][Full Text] [Related]
18. The pathophysiologic basis of efficacy and clinical experience with the new oral antidiabetic agents.
Rosak C
J Diabetes Complications; 2002; 16(1):123-32. PubMed ID: 11872380
[TBL] [Abstract][Full Text] [Related]
19. Glimepiride: role of a new sulfonylurea in the treatment of type 2 diabetes mellitus.
Campbell RK
Ann Pharmacother; 1998 Oct; 32(10):1044-52. PubMed ID: 9793597
[TBL] [Abstract][Full Text] [Related]
20. A placebo-controlled, randomized study of glimepiride in patients with type 2 diabetes mellitus for whom diet therapy is unsuccessful.
Schade DS; Jovanovic L; Schneider J
J Clin Pharmacol; 1998 Jul; 38(7):636-41. PubMed ID: 9702849
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]